{"entity":{"id":"nct03611868","kind":"trial","name":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in melanoma and uveal melanoma, run by Ascentage Pharma Group Inc., active and no longer recruiting.","summary":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03611868 by Ascentage Pharma Group Inc., with 230 participants planned, started 2018-08-29 and due to reach its primary completion in 2025-12-30. Interventions recorded: Phase 1b: APG-115+pembrolizumab. Conditions listed: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03611868","url":"https://clinicaltrials.gov/study/NCT03611868"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","uveal-melanoma","advanced-melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03611868","phase":"1/2","setting":"A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors","sponsor":"Ascentage Pharma Group Inc.","participation":[{"nct":"NCT03611868","source":"https://clinicaltrials.gov/study/NCT03611868","fetchedAt":"2026-10-07T16:53:05.351Z","studySha256":"53c4f481810ae157fbc453e3d8785cb83d7b8821aee5dd612f624fa1931899c2","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-08-07","leadSponsor":"Ascentage Pharma Group Inc.","collaboratorCount":1,"minimumAge":"12 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":230,"enrolmentType":"ESTIMATED","siteCount":21,"recruitingSiteCount":0,"countries":["Australia","United States"]}],"started":"2018-08-29","startedType":"actual","enrolled":230,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03611868/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}